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ABSTRACT

THE EFFECT OF THE LOSS OF LGL1 IN MURINE NEURAL PROGENITOR
CELLS ON MAPK SIGNALING AND PROLIFERATION

Monique LaCourse

Glioblastoma is an incurable, aggressive, and highly invasive type of brain tumor
that harbors tumor initiating cells characterized by disrupted polarized cell divisions. A
cell polarity gene lethal (2) giant larvae 1 (Lgl1) has been implicated in gliomas and is a
tumor suppressor initially identified in Drosophila with roles in proliferation. The loss of
Lgl1 in Drosophila activates the MAPK protein kinase JNK and the Ras pathway and
therefore its downstream kinase ERK, a transcription factor modulator. Furthermore,
when Lgl1 is knocked out in mice, a phenotype similar to glioma is seen. Loss of the
human form of Lgl1, Hugl1, and increases in c-Jun, an oncogene and JNK target, has
been associated with glioma in humans. Additionally, the protooncogene transcription
factor c-Myc is documented in glioma to directly correlate to tumor grade and an increase
in an analogous form, d-Myc, in Drosophila has been shown to promote survival of Lgl
mutants through a Ras mechanism. Here we sought to determine if the cancer properties
associated with loss of Lgl in mice and humans are related to changes in MAPK
signaling. To accomplish this, murine neural progenitor cells from the subventricular
zone of mice with a Lgl1 knockout were cultured in vitro. These cells were plated
ii

adherently and characterized for changes in phosphorylation states of MAPK proteins
ERK, JNK and p38 as well as two protooncogene MAPK downstream targets, c-Jun and
c-Myc. In addition, to understand if MAPK phosphorylation is related to proliferation we
characterized the proliferation rates of these cells in the presence of chemical inhibitors
of p38 and ERK’s upstream activating kinase MEK. Differential expression patterns were
observed in MAPK proteins and their downstream targets associated with the loss of
Lgl1, under standard conditions and with the treatment of DMSO as a drug vehicle
control and chemical inhibitors of p38 and MEK. Additionally, it was found that the loss
of Lgl1 in neurosphere culture slightly increased growth and under adherent conditions
this effect was not seen, however, changes did occur in the presence of p38 and MEK
inhibitors. This supports previous data and signifies the importance of MAPK pathway in
cancer phenotypes and beginning to characterize the role of the Lgl1 protein in the
mouse.
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INTRODUCTION

Glioblastoma Origins in Neural Stem and Progenitor Like Cells

Glioblastomas comprise approximately 17% of central nervous system tumors
which are incurable, aggressive, and highly invasive. Their diffuse nature makes surgery
impossible and chemotherapy and radiation treatments rarely increase the mean patient
survival of 14 months (Phuphanick 2017). A characteristic feature which makes them
difficult to treat is their phenotypic heterogeneity due to the glioblastoma cells existing in
different differentiation states (Singh et al. 2004). Genetically-engineered mouse models
have shown glioblastoma tumors to harbor stem-cell like tumor propagating cells
originating from neural stem and progenitor cells which upon transplantation to an
immunocompromised mouse have the ability to regenerate the tumor (as reviewed by
Liebelt et al. 2016; Singh et al. 2004; Llaguno et al. 2009; Sugiarto et al. 2011). These
undifferentiated cells are resistant to current radiation and chemotherapy treatments
signifying they have a key role in glioblastoma recurrence and show the need for further
research to develop treatments to target these cells (Bao et al. 2006; Chen et al. 2012).
Additionally, human and murine glioblastoma tumor propagating cells are characterized
by disrupted polarized cell divisions, increased self-renewal, and impaired differentiation
capacities (Sugiarto et al. 2011). Better understanding the molecular mechanisms behind
these cancer properties could provide insight into the etiology and treatments for this
devastating cancer.
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Lethal Giant Larvae Homolog 1 as a Highly Conserved Cell Polarity Gene

Loss of cell polarity is considered a hallmark of cancer formation and cell
proliferation. Mutations in genes governing asymmetric cell division and apical-basal cell
polarity promote tumor formation in Drosophila and mammals (reviewed in Neumuller
and Knoblich 2009). One of these genes is lethal (2) giant larvae homolog 1 (Lgl1),
which is a membrane bound tumor suppressing protein with roles in cell polarity and
proliferation that is conserved across the eukaryotic kingdom (Gateff 1978; Mechler et al.
1985; Lee et al. 2006; Humbert et al. 2003). The gene was initially characterized in
Drosophila through a genetic screen which found it to contribute to larval morphology
deformities by being a recessive regulator of malignant neuroblastomas. It was named for
its extraordinary ability to create fatal overgrowth in the brain and imaginal discs in
Drosophila (Gateff 1978). It was later identified in Drosophila this dysregulation in
symmetrical division occurred in neuroblasts, stem cells of the developing brain, due to a
signaling disruption between Lgl, Pins, and aPKC (Lee et al. 2006). There are two
mammalian homologues, Lgl1 (Hugl1) and Lgl2 (Hugl2). Similarities in their roles is
related to the conserved structure in the Lgl protein across different species consisting of
multiple WD40 domains which are used as a scaffold for coordination of multiprotein
complex assemblies and contain serine and threonine phosphorylation sites.
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Lgl in Drosophila Development

Mutations in Drosophila lethal giant larvae gene (D-Lgl) causes loss of apicalbasal polarity, loss of epithelial organization, and uncontrolled proliferation (Baek 1999;
Bilder 2001; Humbert et al. 2003; Justice et al. 2003). D-Lgl co-localizes with Discslarge (Dlg) and Scribble to establish and maintain the basolateral domain while
functioning competitively with protein complexes that are necessary for the apical
membrane domain, the Par complex (Par3/Par6/aPKC) and Crumbs complex
(Crumbs/Pals/Patj) (Bilder and Perrimon 2000; Ohshiro et al. 2000; Peng et al. 2000;
Albertson and Doe 2003; Betschinger et al. 2003; Tanentzapf and Tepass 2003). D-Lgl
acts together with Numb, a negative regulator of Notch, a protein related to glial
differentiation and self-renewal of the neural progenitor cell (Betschinger et al. 2003).
Depletion of Lgl upregulates Notch signaling in Drosophila eye tissue and increased
Notch has been noted to prevent differentiation and encourages undifferentiated
proliferation (Parsons et al. 2014). In the Hippo pathway, which has roles in proper
control of cell survival and organ size, loss of Lgl causes deregulation potentially
inducing tumorous tissue growth through an increase in Yorkie activity (Grzeschik et al.
2010; Froldi et al. 2010). Similarly, an increase in Yorkie activity is also seen through
upregulation of one of the mitogen activated protein kinases (MAPK), Jun N-terminal
kinase (JNK) (Sun and Irvine 2013). This work in Drosophila has led to many
mammalian studies to characterize the differences between species and further elucidate
Lgl’s role in development and pathology.
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Lgl1 in Mammalian Development and Pathology

Studies shifted to mammalian model after the promising studies in Drosophila in
hopes to uncover a treatment for pathologies related to Lgl. Lgl1 is broadly expressed in
mice with the highest expression in the brain (Klezovitch et al. 2004). Numb mutant mice
display hyperplasia of the developing cortex (Li et al. 2003). Also related to increased
Notch signaling, in transgenic mice the Lgl1 gene product controls cell cycle exit and
apical-basal polarity of neural progenitor cells. This results in aberrant growth and
symmetric cell division of neuroepithelial cells forming a phenotype similar to glioma
partly due to their inability to differentiate (Klezovitch et al. 2004) (Figure 1). In humans,
it has been suggested that normal polarity signaling is necessary for maintenance of
healthy tissue and disrupted cell polarity may contribute to epithelial-to-mesenchymal
transition and tumorigenesis (Shin et al. 2006; Nakaya and Sheng 2013; Casarsa et al.
2011). However, Lgl’s role in leukemia has been inconsistent and the absence of Lgl1 in
mice does not alter leukemiai by Notch, c-Myc, and Jak2 signaling (Hawkins et al. 2014).
Recent data has suggested opportunities for further research on the mechanism may lie in
the mitochondria related signaling, MAPK and Ras signaling, and mTor signaling
(reviewed in Cao et al. 2015). Overall there remains a gap in truly understanding the
mechanism of action of Lgl1 and its role in cancer particularly in mammalian models
such as mice which showed such a severe and fatal phenotype with the loss of Lgl1
(Klezovitch et al. 2004).
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Figure 1. In vivo murine Lgl1 knockout displays overgrowth of the brain. (A, B) Changes
to the morphology of E12.5 mouse embryos with Lgl1 loss. (C, C’ through E, E’)
Histological changes in brain structure compared to WT samples of E12.5 embryos. D,
D’ and E, E’ represent magnified images of the previous boxed areas. (F, F’ through H,
H’) Histological changes in brain structure compared to WT samples of E15.5 embryos.
G, G’ and H, H’ represent magnified images of the previous boxed areas. Inset of H’
shows an aberrantly localized blood vessel on the ventricular wall. (I, I’) Visualization of
ventricle dilation and damage with loss of Lgl1 function (adapted from Klezovitch et al.
2004).

6
Hugl-1 in Human Glioma

The molecular mechanisms of the human homolog of Lgl is still being understood
in various tissue types and cancers. It has been found that Hugl1 suppresses various
epithelial cancers by inhibiting proliferation and migration and promoting apoptosis and
cell adhesions (Lu et al. 2009; Song et al. 2013; Kuphal et al. 2006). One study found
decreased levels of Hugl1 in human glioma tissues, indicating it is involved in glioma
progression. However, over-expression in vitro either stably or transiently did not affect
glioma cell proliferation or regulate the Hippo pathway as suggested in the Drosophila
model. In an orthotopic model of nude mice with a glioma cell line, over-expression of
Hugl1 inhibited gliomagenesis and proliferation and promoted apoptosis (Liu et al.
2015). Furthermore, Hugl1 is constitutively phosphorylated and inactivated in
glioblastoma cells. Cell motility and invasion of glioblastoma cells was reduced in vitro
and in vivo, respectively, and differentiation promoted in vitro and in vivo when a nonphosphorylatable and constitutively active form of Lgl1 was expressed in a glioblastoma
cell line, in primary patient cells, and in intracerebral xenografts (Gont et al. 2014).
Phosphorylation of Hugl1 was attributed to increased aPKC activity from increased PI 3kinase due to the loss of PTEN of which this loss occurs in 90% of glioblastomas (Gont
2016). While this data supports previous work in Drosophila, the molecular mechanism
of action is still not fully understood in humans and certainly not in mice.
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Mitogen Activated Protein Kinase (MAPK) Pathway

Mitogen-activated protein kinases (MAPKs) are serine-threonine kinases that
mediate intracellular signaling associated with a variety of cellular activities including
cell proliferation, differentiation, survival, death, and transformation (McCubrey et al.
2006; Dhillon et al. 2007). The mammalian MAPK family consists of p38, extracellular
signal-regulated kinase (ERK), and c-Jun N-terminal kinase (JNK). They are comprised
of several isoforms: ERK1 to ERK8; p38-α, -β, -γ, and -δ; and JNK1, 2 and 3 (Schaeffer
and Weber 1999). Each signaling axis to activate these MAPK proteins consists of three
components which phosphorylate each other in the following order: a MAPK kinase
kinase (MAP3K) phosphorylates a MAPK kinase (MAP2K) which in turn phosphorylates
the MAPK. Activated MAPKs phosphorylate various substrate proteins including
transcription factors such as Elk-1, c-Jun, ATF2, and p53 (reviewed in Kim and Choi
2010).
MAPKs have been implicated in numerous functions in many types of cancer
with cancerous mutations being primarily associated with the Ras/Raf/MEK/ERK
pathway while the stress activated pathways, JNK and p38, appear to counteract
malignant formation (reviewed in Dhillon et al. 2007). A summary of the MAPK
pathway can be found in Figure 2. Roles for each have been documented in the properties
associated with glioblastoma.
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Figure 2. Mitogen-activated protein kinase (MAPK) signaling pathways. MAPK
signaling pathways mediate intracellular signaling initiated by extracellular or
intracellular stimuli. MAP3Ks, which are activated by MAP4Ks or GTPases, mediate
phosphorylation and activation of MAP2Ks, which in turn phosphorylate and activate
MAPKs. Activated MAPKs phosphorylate various substrate proteins including
transcription factors, resulting in regulation of a variety of cellular activities including
cell proliferation, differentiation, migration, inflammatory responses, and death. The
mammalian MAPK family includes ERK, p38, and JNK (adapted from Kim and Choi
2010).
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MAPK in relation to Lgl1, neural stem cells, and glioblastoma
ERK. The RAF/ERK signaling pathway is activated during neural stem cell
proliferation and neuronal and astrocytic differentiation (Rhee et al. 2016). Additionally,
the phosphorylation of ERK is necessary for neuronal differentiation and survival of
differentiating cells (Li et al. 2007). The RAS/RAF/MEK/ERK signaling cascade is
implicated in a number of cancers and therefore a common target for chemotherapies and
is even referred to as the “Achilles heel of the MAPK pathway in cancer therapy” (Liu et
al. 2018). Mutations in upstream kinase MEK has led to hyper activation of ERK and
been shown to induce gliomas in vivo with the additional activation of AKT or loss of
Ink4a/Arf. Recently a large genomic screening of various grades of diffuse glioma tissue
found a substantial amount of activating KRAS and NRAS mutations (Ceccarelli et al.
2016). Furthermore, glioma cell proliferation is controlled by ERK activity-dependent
surface expression of PDGFRA in glioma cells. Treatment with a MEK inhibitor induced
an initial inhibition of ERK1/2 phosphorylation, followed by up-regulated ERK1/2
phosphorylation concomitant with diminished surface expression of PDGFRA which
decreased cell proliferation (Chen et al. 2014). Curcumin was found to effect glioma cell
line by activating the ERK pathway and inducing autophagy. When the ERK pathway
was inhibited the curcumin-induced autophagy was inhibited thus enhancing cytotoxicity
(Aoki et al. 2007). PKC isoforms differentially effect ERK with PKC α inducing the
activation of nuclear ERK and PKC ε inducing the activation of ERK at focal adhesions
to mediate glioma cell adhesion and motility (Besson et al. 2001).
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p38. MAPK p38 has been found to have varying roles in different tissues in
relation to inflammation, development, and cancer progression (Bradham and McClay
2006). A p38 scaffold protein assembly induces the of expression of gene programs for
neurogenesis and endogenous p38 has been found to promote migration of adult neural
stem/progenitor cells (Oh et al. 2009; Hamanoue et al. 2016). Additionally, p38
phosphorylate Dlg to promotes it localization to the membrane where it combines with
Lgl to maintain cell polarity (Sabio et al. 2005). The invasive and progressive nature of
glioma has been linked to MKK3 and subsequently p38 activation. The inhibition of
either of these significantly reduced invasiveness in vitro and greatly sensitized glioma
cells to cytotoxic therapies (Demuth et al. 2007). Finally, p38 and JNK pathways were
shown to affect VEGF secretion in malignant glioma cells; therefore, possibly
contributing to VEGF-induced angiogenesis (Yoshino et al. 2006).
JNK. Jun N-terminal kinase (JNK) has a known role in cancer; however, JNK1
and 2 have shown to have different and sometimes opposing roles in different tissues
(Bubici and Papa 2014). JNK1 was found to have an important role in neural
development as knockout mice had aberrant phenotypes (Kuan et al. 1999). In
Drosophila, the loss of Lgl is associated with increased phosphorylation of JNK that
results apoptosis (Di Giacomo et al. 2017; Froldi et al. 2010; Menendez et al. 2010;
Grifoni et al. 2015). Furthermore, phosphorylation of JNKs and c-Jun has been shown to
strongly correlate with the histological grade of glioblastoma and poor prognosis (Li et al.
2008). Elevated levels of JNKs activity was observed in glioblastoma cell lines and in
human tumor tissues with JNK2 having the most pro-tumorigenic role in glioblastoma in

11
comparison to JNK1 and 3 (Antonyak et al. 2002; Li et al. 2008). Sphere and monolayer
culture conditions were evaluated for human glioma stem cell lines. It was found that
JNK signaling and sphere culture was crucial for the maintenance of stemness. JNK2 was
again found to be the most important isoform to maintain stemness and increased
phosphorylation of it and subsequently increased Notch signaling was found in spheres in
comparison with monolayer culture conditions (Yoon et al. 2012). Additionally, JNK
activity is required for the maintenance of stem-like glioblastoma cells. In this study,
human glioma cells were xenografted into mice and a transient and systemic JNK
inhibitor administered. As a result, there was a depletion of self-renewing and tumorinitiating populations, inhibition of tumor formation by stem-like glioblastoma cells in
the brain, and it provided a survival benefit with minimal adverse effect (Matsuda et al.
2012).
c-Jun and Myc. c-Jun and Myc are both proto-oncogenes transcription factors
downstream of MAPKs. c-Jun is activated by JNK through phosphorylation at Ser63,
Ser73, Thr91, and Thr93; and by ERK and p38 via increased gene expression (Chang and
Karin 2001). While Myc activation has been tied to the MAPK family (Zhu et al. 2008).
In Drosophila, poor survival of Lgl mutants due to p-JNK mediated apoptosis was
rescued when dMyc expression or RAS activity was high (Froldi et al. 2010; Menendez
et al. 2010; Grifoni et al. 2015). Therefore, Myc-mediated cell competition was proposed
for cancer survival where there is a direct relationship between fitness and Myc
expression in relation to Hugl (Di Giacomo et al. 2017). Along with this levels of Myc
correlated directly with tumor grade and therefore prognosis (Herms et al. 1999). Myc
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inhibition in vivo and and in vitro for both murine and human cell lines and tissues
reduced proliferation and increased apoptosis (Annibali et al. 2014). On the other hand, it
was found that c-Jun accumulation in glioblastoma was not due to MAPK signaling but
IRES mediated cap-independent translation (Blau et al. 2012).

In Summary

There is evidence that the MAPK family and oncogenes, c-Jun and c-Myc, are
involved with Lgl and glioma to promote cancer survival, progression, and apoptosis.
However, the molecular mechanisms connecting the dots between various pathways are
poorly understood and therefore targeted drugs with minimal adverse effects are difficult
to develop. Additionally, it remains unclear whether loss of polarity is a consequence of
uncontrolled proliferation or a causative factor in cancer initiation. To further elucidate
the effects of these proteins and proliferation in relation to Lgl, we will use murine neural
progenitor cells with Lgl1 knocked out and MAPK small molecule inhibitors.
Specifically, SB203580 will be used to inhibit the phosphorylation of p38 by binding to
the ATP-binding pocket and PD0325901 to inhibit MEK and therefore its downstream
targets such as ERK1/2.
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STATEMENT OF AIMS

These aims are designed to elucidate the role of Lgl1 in the mouse in relation to MAPK
signaling and proliferation. There is a strong correlation with cell polarity in cancer
phenotypes and Lgl1’s role in the brain. It is not known the molecular mechanisms
behind Lgl1’s role in glioma like phenotypes in the mouse and how proliferation relates.
A summary of the experimental design to accomplish these aims can be found in Figure
3.
1.) Does loss of Lgl1 affect MAPK signaling?
This aim is designed to evaluate the effect of the loss of Lgl1 in murine neural
progenitor cells on MAPK signaling pathways. We hypothesized there would be changes
to MAPK signaling specifically an increase in activity with the loss of Lgl1. To evaluate
this, murine neural progenitor cells isolated from the subventricular zone of neonatal
mice with the Lgl1 gene knocked out were cultured under conditions that support the
analysis of growth and proliferation. Total cytoplasmic protein was isolated from these
cells cultured either under standard conditions or in the presence of MAPK inhibitors.
Immunoblots for the endogenous and phosphorylated forms of MAPKs were evaluated.
Fold changes were calculated from the normalized densitometry values to evaluate the
effect of the loss of Lgl1 and MAPK inhibitors.
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2.) Does loss of Lgl1 affect expression and phosphorylation of classic MAPK targets
involved in proliferation and cancer?
This aim is designed to characterize MAPK activity by evaluating the effect of the
loss of Lgl1 in murine neural progenitor cells on classic MAPK targets through
immunoblot analysis. We hypothesized there would be increased expression and
phosphorylation of oncogenes c-Jun and c-Myc correlated with an increase in MAPK
activity.As described in Aim 1, total nuclear proteins were isolated from these cells after
treatment with MAPK inhibitors followed by a fold change analysis of the normalized
densitometry values.
3.) Does loss of Lgl1 change proliferation alone and/or in the presence of MAPK
inhibitors in primary murine neural progenitor cells?
This aim is designed to evaluate the effect of loss of Lgl1 alone and/or in the
presence of MAPK inhibitor in murine neural progenitor cells on proliferation as an
adherent culture. We hypothesized the loss of Lgl1 would increase proliferation and this
increase would not be seen when the MAPKs are inhibited. The cells were plated
adherently in a 96 well plate in quadruplicate alone and in the presence of MAPK
inhibitors. The CyQuant cell proliferation assay was used to assess cell growth over 96
hours with a fluorometric output based on DNA content.
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Figure 3. Experimental design. Neural progenitor cells from the subventricular zone of
mice 7018 and 8322 with Lgl1 knocked out were plated adherently and treated with an
inhibitor for p38, 10 µM SB203580, and an inhibitor for MEK, 1.0 µM PD0325901.
Immunoblots were used to evaluate the first and second aim designed to see if the loss of
Lgl1 changes MAPK signaling or their downstream targets, c-Jun and c-Myc. To evaluate
the third aim of the effect of Lgl1 on proliferation a 96-well fluorescent proliferation
assay was used.
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METHODS

Neural Progenitor Cell Maintenance Culture Conditions

Primary neural progenitor cells were isolated from the subventricular zone of
adult Lgl1loxp/loxp mice (Klezovitch et al. 2004) by a postdoctoral fellow in the Petritsch
laboratory at UCSF’s Helen Diller Cancer Center. The cells were treated with adenovirus
containing either GFP or GFP-Cre to create genetically matched Lgl1+/+ and Lgl1-/primary neural progenitor cells for biological replicates 7018 and 8322 at passage six and
two, respectively. The cells were propagated and maintained as neurospheres in ultra-low
adherent vessels at a density of 25,000 cells/mL in neurobasal-A medium (Gibco
#10888022) supplemented with 1:50 vitamin B27 without vitamin A (Gibco #12587010)
and 1:100 L-glutamine (Gibco #25030081) along with epidermal growth factor (Sigma
Aldrich #E9644) and fibroblast growth factor (Pepro-Tech #100-18B) every other day.
They were incubated at 37°C and passaged when the spheres started to darken in the
center every 4-6 days with Accutase (Corning #MT25058Cl) at 37°C for 5-8 minutes.
They were cryopreserved in basal media supplemented with 10% DMSO and 20% BIT
9500.
Adherent Culture Conditions

Biological replicate 7018 at passage 10, 11, and 12 and 8322 at passage 11 and 12
were used for adherent conditions. Replicates 7018 p10 and the passage 11 cells came
from cryopreservation then cultured as spheres for 5 days prior to being harvested for
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adherent culture. The passage 11 cells were then plated back and continued as spheres for
harvest and plating as adherent at passage 12. Culture vessels were coated with poly-Lornithine (Millipore A-004-C) at 15 µg/mL in phosphate buffered saline (PBS) for 30
minutes at room temperature, washed three times with PBS, then coated with laminin
(Corning #354239) at 6.1 µg/mL in PBS at 37°C for 3 hours. Cells were maintained as
spheres for 5 days except for 8322 p2+12 for 6 days. A single cell solution was prepared
with Accutase by straining the cells with a 37-micrometer strainer (STEMCELL #27250).
Biological replicate 7018 at passage 10, 11, and 12 and 8322 at passage 11 and 12 were
plated adherently at 30,000 cells/cm2 for 24 hours prior to treatment. Cells cultured under
standard conditions were evaluated for the effects of Lgl1 only. To assess how loss of
Lgl1 affected p38 and ERK signaling, cells were cultured in SB203580 at 10 µM
(Adipogen Syn-1074) or PD0325901 at 1.0 µM (SelleckChem S1036). The inhibitors
were dissolved in DMSO (Tocris 31-762) and applied to the cells at 1:2000; therefore, a
drug vehicle control culture received DMSO at 1:2000.
Immunoblots

Cells were harvested with Accutase (Corning #MT25058Cl) after 2 hours of
treatment with inhibitors and pelleted for protein extraction. NE-PER Nuclear and
Cytoplasmic Extraction Reagents were used to extract cytoplasmic and nuclear protein,
then the proteins were quantified with a BCA assay according to manufacturer
instructions (Thermo Fisher #78835, #23227). Proteins were denatured at 95°C for 5
minutes in 6x Laemmli buffer. Samples were run at 110 volts at 4°C in precast Novex 10-
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20% Tris-glycine gels (Invitrogen #XP10205) in 1X SDS running buffer. Proteins were
transferred to a PVDF membrane activated in 100% methanol (Millipore #IPVH00010)
in cold transfer buffer (1X Tris-Gly Buffer, 20% Methanol and ddH2O to volume) at 20V
for 2-8 hours at 4°C. The membrane was place in blocking buffer (1X TBST, 1% BSA
and 0.1% nonfat milk) for 15 minutes on a rocker prior to primary antibody diluted in
blocking buffer being applied and incubated overnight at 4°C. Primary antibodies applied
were c-Jun, p-c-Jun (Ser63), c-Myc, p38, p-p38, ERK, p-ERK, JNK, p-JNK, and
GAPDH (Appendix A). After washing the membrane three times in 1X TBST on a
rocker, a horseradish (HRP) peroxidase conjugated secondary protein (Thermo Fisher
#31460) was applied for 1 hour diluted 1:2000 in blocking buffer at room temperature.
Following three more washes in 1X TBST the blot was developed with WesternSure
Premium Chemiluminescent Substrate (Li-Cor #C50528-02) prepared at a 1:1 ratio
immediately prior to imaging with the Li-Cor-C-Digital blot scanner. GAPDH was used
as a loading control and initial blots were run with 1.5-2 µg protein to confirm
concentration by densitometry. Nuclear blots were loaded with 3-5 µg of protein and
cytoplasmic with 8-10 µg protein. Following the imaging of the primary antibody, all
blots were acid stripped (Thermo Fisher #21059) for 5-10 minutes to obtain a GAPDH
loading control for each gel run. After stripping the membrane was washed for
thoroughly three times on a rocker, blocked again for 15 minutes, and GAPDH primary
antibody applied at 1:2000 for 1 hour at room temperature. Secondary antibody
application and imaging steps remain the same. Densitometry was performed with Image
Studio and Microsoft Excel used to analyze the output.
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Proliferation Assay

Plates with 96-wells were coated for adherent culture and a single cell suspension
prepared and plated as detailed above with a multi-channel pipettor. Cells were allowed
to adhere for 4 hours before the first time point was taken and DMSO or drugs were
added as detailed above. Each time point was run in quadruplicate and due to the nature
of the reagents, a separate set of cells were plated for each timepoint. The CyQuant NF
Cell Proliferation Assay Kit was utilized, and plates were visualized with a Spectramax i3
Plate Reader.
Data Analysis

Western blot
Densitometry values were obtained with Image Studio. Values of proteins of
interest were normalized to conserved glycolysis gene, GAPDH, and phosphorylated
forms of the proteins were also normalized to their endogenous protein level. Fold
changes were calculated between genotype, Lgl1-/-/Lgl1+/+, for no treatment. To evaluate
the treatments and control for the effect of drug vehicle, first the fold change between
treatment within genotype was calculated as follows: DMSO/NT, SB/DMSO, and
PD/DMSO. Those fold change values were used to create a fold change between
genotype, Lgl1-/-/Lgl1+/+. Heat maps were created according to the color values recorded
in Table 1. Additionally, a one sample t-test was performed on the log of the fold change
values with a p-value of 0.05.
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Proliferation
The most dissimilar value from the average was removed from all quadruplicates
before the fluorescent output values were averaged. Fold changes for the different
conditions and heat maps were created in the same manner as the western blots.
Additionally, a one sample t-test was performed on the log of the fold change values with
a p-value of 0.05.
Table 1. Fold change heat map key. Key for fold change heat maps of western blot
densitometry values and proliferation fluorescence output. The miniscule effect was only
evaluated in the proliferation data.
Heat Map Key
Fold Change Range Color Indication
≥ 2.0

Increase

= 1.8- 2.0

Mild increase

= 1.5- 1.8

Slight increase

= 1.3- 1.5

Miniscule increase

= 0.85- 1.3

No effect

= 0.75- 0.85

Miniscule decrease

= 0.6- 0.75

Slight decrease

= 0.5- 0.6

Mild decrease

≤ 0.5

Decrease

N/A

Not present or evaluated

≤ 0.25 or ≥ 4.0

*

Strong decrease or increase
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RESULTS

Sphere Culture Propagation and Harvest

Neural progenitor cells were maintained and propagated as spheres for 5 days
except 8322 p12 for 6 days due to slow and abnormal growth. Cells were harvested with
92.5- 98.9% viability as determined by trypan blue prior to plating under adherent
conditions after 5 days of growth (Appendix D). The loss of Lgl1 slightly increased
sphere growth except in 7018 p11 with an average fold change of 1.34 including 7018
p11 and 1.44 excluding 7018 p11 (Appendix E).
Loss of Lgl1 Affects MAPK Signaling

Low yields of protein extract were obtained particularly in cells treated with
PD0325901 (MEK/ERK inhibitor), of higher passage, and in 8322. Cells of passage 12
and in particular 8322 had less cells adhered after 24 hours in comparison to 7018 and
passage 10 and 11. Furthermore, upon addition of PD0325901 for 2 hours, the majority
of cells were no longer adhered. Therefore, data for c-Jun, JNK1/2/3, and p-JNK1/2/3 is
not complete for all replicates. In particular, c-Jun was not evaluated in 7018 p11 for any
treatment and in 8322 for cell treated with PD0325901 in Lgl1-/-. Additionally, JNK was
not evaluated in 8322 and p-JNK was not evaluated in 8322 p12.
Immunoblot data was highly variable across replicates. Despite fold changes of at
least 1.5 or 0.75 in multiple replicates, a one sample t-test on the log of the fold changes
revealed few genes with a significant change due to the loss of Lgl1 (p-value ≤ 0.05).
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With a p-value of 0.05, the loss of Lgl1 significantly affected the phosphorylation of p38
when normalized to p38 (t= 2.80, df= 4, p-value= 0.049) in the presence of a p38
inhibitor, 10 µM SB203580, and the phosphorylation of JNK p54 when normalized to
GAPDH (t= 10.34, df= 2, p-value= 0.009) in the presence of a MEK inhibitor, 1.0 µM
PD0325901 (Table 2). Additionally, 7018 p10 lacked a p-JNK p54 band and a band
slightly larger than p-p38 was visualized in 7018 p11 for cells treated with SB203580
only and in all treatments for 8322 p11 (Appendix H, J).
Overall, the loss of Lgl1 and inhibitors affecting the MAPK pathway did not have
an effect on endogenous levels of MAPK proteins. The loss of Lgl1 had no effect on p38
and JNK levels and a preferential decrease in 8322 of ERK1/2. In the presence of DMSO,
there was no effect on p38 except a slight decrease in passage 11, an increase in ERK1, a
preferential increase in 8322 of ERK2, no effect in 7018 in JNK p54, and a slight
decrease in JNK1/2/3 p54 in 7018. In the presence of a p38 or MEK inhibitor there was
no effect on p38, ERK1/2, and JNK p46/p54 (7018 only) (Figure 4).
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Table 2. Minimal significant changes to MAPK signaling with the loss of Lgl1. The pvalues from a one sample two-tailed t-test on log fold change of densitometry values of
western blots from adherent cultures treated for 2 hours with nothing, 1:2000 DMSO, 10
µM SB203580 (p38 inhibitor), and 1.0 µM PD0325901 (MEK inhibitor). Densitometry
values of proteins of interest were normalized to GAPDH and the phosphorylated forms
also normalized to their endogenous levels. Fold changes were calculated between
-/-

+/+

genotype, Lgl1 /Lgl1 , for no treatment. To evaluate the treatments and control for the
effect of drug vehicle, first the fold change between treatment within genotype was
calculated as follows: DMSO/NT, SB/DMSO, and PD/DMSO. Those fold change values
-/-

+/+

were used to create a fold change between genotype, Lgl1 /Lgl1 . Bolded text indicates
a significant change due to loss of Lgl1 with a p-value of 0.05 or less.

Norm to: Gene
GAPDH
GAPDH
cJun
GAPDH
GAPDH
GAPDH
p38
GAPDH
GAPDH
ERK
GAPDH
GAPDH
ERK
GAPDH
GAPDH
JNK
GAPDH
GAPDH
JNK

cJun
p-cJun
p-cJun
c-Myc
p38
p-p38
p-p38
ERK1
p-ERK1
p-ERK1
ERK2
p-ERK2
p-ERK2
JNK p54
p-JNK p54
p-JNK p54
JNK p46
p-JNK p46
p-JNK p46

1- sample t-test p-value
NT
DMSO SB203580
1:2000 10 µM
0.369 0.339
0.400
0.137 0.087
0.544
0.280 0.057
0.617
0.382 0.138
0.284
0.893 0.454
0.238
0.442 0.588
0.464
0.442 0.655
0.049
0.048 0.520
0.140
0.894 0.872
0.426
0.588 0.851
0.087
0.158 0.135
0.257
0.434 0.977
0.612
0.276 0.319
0.750
0.979 0.525
0.352
0.196 0.771
0.181
0.225 0.911
0.438
0.586 0.743
0.268
0.067 0.437
0.847
0.224 0.774
0.825

PD0325901
1.0 µM
0.172
0.524
0.387
0.589
0.678
0.361
0.482
0.491
0.452
0.151
0.660
0.588
0.521
0.542
0.009
0.141
0.366
0.941
0.846
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A.)

B.)
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C.)

D.)

Figure 4. The loss of Lgl1 affects MAPK signaling and downstream targets, c-Jun and cMyc. Heat maps (refer to Table 1 for key) of fold changes between genotype (Lgl1
+/+

-/-

/Lgl1 ) for western blot densitometry values and proliferation fluorescent output data
for adherent cultures from mice 7018 and 8322 at passage 10, 11, and 12. Westerns were
normalized to GAPDH and the phosphorylated form to the endogenous protein of
interest. Proliferation data was collected over 96 hours with data points every 24 hours;
this data was normalized to the 24-hour time point. Treatments/inhibitors were added at
plating for proliferation and after 24 hours for westerns; they were then normalized to the
drug vehicle control, DMSO, to control for its affect. A.) Represents data for no treatment
(NT) where the culture was adhered for 26 hours. B.) Represents data for DMSO, the
drug vehicle, at 1:2000 after 2 hours in culture normalized to NT to evaluate its affect. C.)
Represents data for cells treated with 10 µM SB203580 for 2 hours and normalized to the
drug vehicle, DMSO at 1:2000. D) Represents data for cells treated with 1.0 µM
PD0325901 for 2 hours and normalized to the drug vehicle, DMSO at 1:2000.
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The loss of Lgl1 had no effect on phosphorylation of p38, an increase in
phosphorylation of ERK1/2, a preferential increase in 8322 of phosphorylation of p-JNK
p54 in, and an increase in the phosphorylation of JNK p46. In the presence of DMSO, the
loss of Lgl1 had no effect on the phosphorylation of p38 and JNK p54 and a decrease in
phosphorylation of ERK1/2 and JNK p46. DMSO reverses the effect of the loss of Lg1l
in no treatment with ERK1/2 and JNK p46 from increased to decreased levels. The p38
and MEK inhibitors had increased sensitivity with the loss of Lgl1 decreased the
phosphorylation of p38 and ERK in comparison to no treatment. In the presence of a p38
inhibitor, the loss of Lgl1 decreased phosphorylation of p38, increased phosphorylation
on ERK1, increased phosphorylation of ERK2 in 7018 and decreased it 8322, and was
inconclusive on the phosphorylation of JNK. In the presence of a MEK inhibitor (effect
of drug vehicle controlled), the loss of Lgl1 decreased the phosphorylation of p38, had no
effect on the phosphorylation of ERK1 and JNK p54, and was inconclusive for the
phosphorylation of ERK2 and JNK 46 (Figure 4).
Loss of Lgl1 Affects the Expression and Phosphorylation of c-Jun and c-Myc

For reasons mentioned above, due to lack of sample, c-Jun was not evaluated in
7018 p11 for any treatment and in 8322 for cells treated with PD0325901 in Lgl1-/-.
Additionally, the loss of Lgl1 in the presence of the MEK inhibitor, 1.0 µM PD0325901,
in 8322 p11 completely shuts down the phosphorylation of c-Jun at serine 63 and c-Myc
levels (Figure 5).
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Overall, the MEK inhibitor drastically decreased the amount of c-Jun in Lgl1-/-cells. As
well as c-Myc levels and the phosphorylation of c-Jun at serine 63 in both genotypes and
preferentially in the Lgl1-/-cells and in 8322. The p38 inhibitor, 10 µM SB203580, also
decreased c-Jun and c-Myc levels and affected the phosphorylation of c-Jun. DMSO had
a notable effect on the Lgl1-/-cells by decreasing c-Myc levels and the phosphorylation of
c-Jun. While the loss of Lgl1 alone had no effect on c-Jun and c-Myc levels and a
decrease on the phosphorylation of c-Jun. In the presence of DMSO, there was no effect
on c-Jun levels and a decrease in c-Myc and the phosphorylation of c-Jun. The p38
inhibitor increases c-Jun and c-Myc levels preferentially in 7018 and decreases
phosphorylation of c-Jun. The MEK inhibitor decreases c-Jun levels, affects the
phosphorylation of c-Jun, and increases c-Myc levels in 7018 while decreasing them in
8322 (Figure 4).

Figure 5. MEK inhibitor, PD0325901 at 1.0 µM, completely inhibits phosphorylation of
-/c-Jun and expression of c-Myc in 8322 p11 in Lgl1 cells. Immunoblot normalized to
GAPDH from biological replicate 8322 p11 under adherent conditions following 2 hours
of treatment with inhibitors. Labels are defined as follows: no treatment (NT), DMSO at
1:2000 (DMSO), 10 µM SB203580 (SB10), 1.0 µM PD0325901 (PD1.0).
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Exceptions of note exist in data generated from replicate 7018 p11 which had an
anomalous strong decrease in the phosphorylation of ERK1/2 with the loss of Lgl1 and in
the presence of DMSO an increase in the phosphorylation of ERK1/2. Additionally, in
7018 p12 in the presence of DMSO, a decrease in c-Jun and c-Myc levels were associated
with an increase in ERK1 levels and the phosphorylation of p38 and JNK1. The opposite
effect was seen in 7018 p12 in the presence of a p38 inhibitor where there is an increase
in c-Jun and c-Myc levels (Figure 4).
Loss of Lgl1 Affects Proliferation

The proliferation assay was performed under neurosphere and adherent culture
conditions. Spheres tended to clump together more in 96 well plates and the reagent for
the assay could not fully penetrate the spheres leading to inconsistent data. Therefore,
adherent culture conditions were used to evaluate proliferation and MAPK signaling with
western blots. No significant difference in proliferation was seen with the loss of Lgl1
under any treatment with a p-value of 0.05 (Table 3).
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Table 3. No significant change in proliferation with the loss of Lgl1. One sample two-/+/+
tailed t-test p-values for fold change (Lgl1 /Lgl1 ) of proliferation rates of spheres over
5 days of growth and adherent culture over 4 days of growth normalized to the 24-hour
timepoint. In sphere data, 8322 p12 was excluded since it grew for 6 days. In
proliferation data, 7018 p10 and 8322 p12 were excluded due to loss of potency in
reagents. Adherent cultures were allowed to adhere for 4 hours prior to treatment with
nothing (NT), DMSO (1:2000), 10 µM SB203580 (SB), and 1.0 µM PD0325901 (PD).
-/+/+
Fold changes were calculated between genotype, Lgl1 /Lgl1 , for no treatment and
sphere data. To evaluate the treatments and control for the effect of drug vehicle, first the
fold change between treatment within genotype was calculated as follows: DMSO/NT,
SB/DMSO, and PD/DMSO. Those fold change values were used to create a fold change
-/+/+
between genotype, Lgl1 /Lgl1 . With a p-value of 0.05 there was no significant change
in proliferation due to the loss of Lgl1.
Proliferation 1- sample t-test p-values
Culture condition Treatment P-value
Sphere
NT
0.057
Adherent
NT
0.572
DMSO
0.477
SB
0.872
PD
0.202
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Adherent proliferation data on 7018 p10 and 8322 p12 was discarded due to the
light and temperature sensitive reagents losing potency. The loss of Lgl1 caused a slight
increase in proliferation in sphere culture which was not found in adherent culture except
in 7018 p12 (Figure 6). In the presence of DMSO, there was a slight decrease in
proliferation with the loss of Lgl1 in adherent culture except in 7018 p12. The addition of
a p38 inhibitor only caused an increase in 8322 p11 and in the presence of a MEK

Fold Change (Loss of Lgl1-/-/Loss og
Lgl1+/+)

inhibitor decreased proliferation in all replicates and preferentially in 8322 (Figure 4, 7).
2.50
2.00
1.50
sphere

1.00

adherent
0.50
0.00

sphere
adherent

7018 p10

7018 p11

7018 p12

8322 p11

1.31

1.65

1.05

1.36

1.34

1.91

0.70

Figure 6. The loss of Lgl1 causes a slight increase in proliferation in sphere culture
-/+/+
conditions. Fold change (Lgl1 /Lgl1 ) of proliferation rates of spheres over 5 days of
growth and adherent culture over 4 days of growth normalized to the 24-hour timepoint.
The loss of Lgl1 slightly increases the proliferation of spheres in comparison to adherent
culture conditions except in 7018 p12.
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Figure 7. Inconsistent changes in proliferation with the loss of Lgl1 under adherent
-/+/+
culture conditions. Heat map of fold change (Lgl1 /Lgl1 ) of proliferation data. Spheres
were grown for 5 days and adherent cultures for 4 days and normalized to the 24 hour
timepoint. Cultures were allowed to adhere for 4 hours prior to treatment with nothing,
DMSO (1:2000), SB203580 (10 µM), and PD0325901 (1.0 µM). Fold changes were
-/+/+
calculated between genotype, Lgl1 /Lgl1 , for no treatment and sphere data. To
evaluate the treatments and control for the effect of drug vehicle, first the fold change
between treatment within genotype was calculated as follows: DMSO/NT, SB/DMSO,
and PD/DMSO. Those fold change values were used to create a fold change between
-/+/+
genotype, Lgl1 /Lgl1 . The color in the replicate label reflects the fold change of the
sphere growth.

The increase in proliferation seen with a p38 inhibitor in 8322 p11 was associated
with an anomalous decrease in c-Jun and c-Myc levels and the phosphorylation of c-Jun.
The decrease in proliferation seen in the presence of an MEK inhibitor was associated
with a decrease in c-Jun levels. The preferential decrease in proliferation in 8322 p11
with the MEK inhibitor was associated with a decrease in c-Myc levels that was
preferential in 8322 and an anomalous increase in phosphorylation of p38 (Figure 7).
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DISCUSSION

We found differential expression patterns associated with the loss of Lgl1 in
MAPK proteins and their downstream targets under standard conditions and with the
treatment of DMSO and chemical inhibitors of p38 (10 µM SB203580) and MEK/ERK
(1.0 µM PD0325901). Additionally, changes to growth and proliferation were found due
to the loss of Lgl1 in the presence of p38 and ERK inhibitors. These results signify the
importance of MAPK pathway in cancer phenotypes and the beginning of characterizing
the role of Lgl1 in the mouse.
Loss of Lgl1 Affects MAPK Signaling

Immunoblot analysis shows loss of Lgl1 increased the amount of phosphorylated ERK in
both 7018 and 8322 cell lines and a preferential increase in p-JNK p54 in 8322 (Figure
4A). The drug vehicle, DMSO, had a significant effect on ERK levels and the
phosphorylation levels of ERK and JNK. DMSO has been found to have a significant
effect on development of embryonic stem cells with morphological changes to embryoid
bodies and downregulation of stemness factors (Pal et al. 2011). Additionally,
hyperosmotic stress induced by the addition of DMSO in HeLA cells was found to result
in the breakage of the cortical cytoskeleton and the detachment of the cell membrane
from the cortical cytoskeleton, causing the formation of cell blebs (Ruan et al. 2015). In
melanoma cells, continued exposure to DMSO resulted in cytoskeletal reorganization
characterized by thick and regularly oriented microfilament bundles that led to increased
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adhesion to the substrate and inhibited cell growth (Lampugnani et al. 1987). In this
experiment, passage 12 had an extra passage of sphere propagation from cryopreservation
where they were exposed to DMSO as well, another source of variation between
replicates.
The cells were plated on poly-L-ornithine which has been shown to promote
differentiation through an ERK mediated mechanism. p-ERK has also been found to be
necessary for differentiation (Ge et al. 2015). Additionally, 8322 had lower protein
yields which could suggest a p-JNK- induced apoptosis often seen with the loss of Lgl1
in Drosophila if there is not an increase in c-Myc (Di Giacomo et al. 2017). DMSO
reversed the effects seen under standard conditions with ERK and JNK and decreased cMyc, a stemness marker. This could be explained by the effect DMSO has on
differentiation and its associated decrease of stemness markers (Pal et al. 2011).
The inhibitors were functional and preferential with the loss of Lgl indicating that
MAPKs affect cellular functions differently with the loss of Lgl. Unfortunately, due to
the biological variation between replicates and not deep enough of an analysis, the
molecular mechanism was not able to be determined. Of note there was an increase in
phosphorylation of ERK2 in 7018 and decreased it 8322 which could be associated to the
more sensitive nature of 8322 due to the knockout being induced at an earlier passage. In
the presence of a MEK inhibitor the loss of Lgl1 decreased the phosphorylation of p38
potentially indicating a loss in the invasive ability of the cells.
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We did not observe consistent upregulation of JNK or an increase the
phosphorylation of JNK which has been noted numerous times (Yoon et al. 2012; Di
Giacomo et al. 2017; Grifoni et al. 2015; Froldi et al. 2010; Menendez et al. 2010). This
could be attributed to the monolayer conditions as reported in Yoon et al. 2012.
Biological replicate 8322 and in particular passage 12 grew oddly as spheres and upon
harvest had low protein yields. Unfortunately, the low protein yields led to insufficient
protein to evaluate JNK in order to test the hypothesis that p-JNK is related to apoptosis.
Variation seen in the replicates could be attributed to differences in the mice and
isolates from their brains since the cells were not sorted. Additionally, 8322 had the
knockout induced at p2 and 7018 at p6. In both sphere and adherent culture 8322’s were
consistently more sensitive and less robust. Furthermore, these cells were primary cells
approaching higher passages. They have been culture by many different students over the
years with varying reagents before being used for these experiments. In this study, it was
attempted to minimize this variation by harvesting the samples over 3 weeks with one
person performing the experiments and culturing them with reagents from the same lot
number.
Loss of Lgl1 Affects c-Jun and c-Myc

Blau et al. 2012 found that changes in c-Jun were not consistently associated with
changes in MAPK signaling in glioblastoma which would support an alternative
translation model. They found that c-Jun protein accumulation was not associated with an
increase in c-Jun mRNA. Instead a potent internal ribosome entry site was discovered
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that direct cap-independent translation in glioblastoma cells (Blau et al. 2012). The
changes observed could be associated with alternative translation.
The strongest increase in c-Myc due to the loss of Lgl1 occurred in the presence
of the p38 inhibitor in 7018 p12. This correlated with the strongest decrease in p-JNK
p46 and an increase p-ERK which would support previous data which c-Myc promotes
survival in relation to an increase in RAS activity and the cells are rescued from p-JNK
initiated apoptosis (Grifoni et al. 2015).

The loss of Lgl1 Affects Proliferation

The loss of Lgl1 in spheres slightly increased proliferation indicating a stemness
property that was seen in a previous study that compared sphere and monolayer culture in
glioblastoma cell lines (Yoon et al. 2012). The MEK inhibitor decreased proliferation in
both genotypes and preferentially with the loss of Lgl1, indicating a potential treatment
for Lgl1 related cancers.
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SUMMARY

Further experimentation must be completed to conclusively determine MAPK’s
role in relation to Lgl1 with statistical relevance. It would useful to be able to differentiate
between the JNK isoforms and focus on the role of JNK2 (Yoon et al. 2012). Sphere
culture should be revisited due to the effects of adherent substrates and data supporting
stemness in spheres. Glioma stem cells could be obtained and Lgl1 knocked down and
overexpressed while performing the same experimental design. In vivo studies in the
mouse evaluating these pathways would be of interest to remove the artifacts of in vitro
studies. Immunohistochemistry on Lgl1 knockout mouse brains for MAPKs and their
targets could reveal a clearer role or possible stratification in the overgrowth. Coupled
with immunohistochemistry of post-mortem human glioblastoma tumors for comparison
of signaling and patterns within the tumor.
Many Ras/Ref/MEK/ERK inhibitors are being developed and explored for use in
treating a number of different cancers. However, just as the MEK inhibitor, PD0325901
at 1.0 µM, had extreme effects on the cells used in this experiment, a lot of inhibitors
comes with similar devastating side effects in vivo. Understanding in greater detail how
mutations and activations in that pathway function will help to create a more targeted
drug.
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APPENDICES

Appendix A. Antibodies used for western blots. List of antibodies and their
manufacturers and dilutions used for western blots.
Antibody
Dilution Manufacturer
Catalog #
cJun

1:500

Abcam

31419/32137

p-cJun S63

1:500

Abcam

32385

cMyc

1:500

Cell Signaling

5605

p-p38

1:500

Cell signaling

9211

p38

1:500

Cell signaling

9212

p-ERK

1:500

Cell signaling

4370

ERK

1:500

Cell signaling

4695

p-JNK

1:1000

Abcam

124956

JNK

1:1000

Abcam

179461

Lgl

1:1000

Abcam

39292

CD133

1:500

Thermo Fisher

Pa5-38014

GAPDH

1:2000

Abcam

181602

Thermo Fisher

31460

2° Anti-Rb HRP 1:2000
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Appendix B. Cell culture reagents and supplies. List of cell culture reagents and supplies
used with catalog numbers and concentrations.
Reagent
Manufacturer Catalog #
Concentration
Neurobasal-A

Gibco

10888022

1X

Vitamin B27 w/o Vit A Gibco

12587010

1:50

L-glutamine

Gibco

25030081

1:100

EGF

Sigma-Aldrich

E9644

20 ug/mL

FGF

Pepro-tech

100-18B

20 ug/mL

Accutase

Corning

MT25058CI --

Laminin

Corning

354239

6.1 ug/mL

Poly-O

Millipore

A-004-C

15 ug/mL

BIT 9500

STEMCELL

09500

1X

DMSO

Tocris

31-762

1:2000

SB203580

Adipogen

Syn-1074

10 uM

PD0325901

SelleckChem

S1036

1.0 uM

37 micron cell strainer

STEMCELL

27250

--
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Appendix C. Reagents and kits used for immunoblots and proliferation assay. List of
reagents and kits along with catalog numbers to perform immunoblots and proliferation
assay.
Reagent/Kit
Manufacturer Catalog #
NE-PER Nuclear and Cytoplasmic Extraction Reagents Thermo Fisher

78835

Pierce BCA Protein Assay Kit

Thermo Fisher

23227

Bovine serum albumin

Thermo Fisher

BP9706100

CyQuant NF Cell Proliferation Assay Kit

Invitrogen

C35006

Novex Tris-Glycine 10-20% gels

Invitrogen

XP1020_

PVDF membrane

Millipore

IPVH00010

WesternSure Premium Chemiluminescent Substrate

Li-Cor

C50528-02

Stripping Buffer

Thermo Fisher

21059
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Appendix D. Viability of neurospheres harvested for adherent assays was consistently
above 92%. Percent viability of neurospheres harvested for adherent culture assays.
100

Percent Viability

95
90
Lgl1+/+

85

Lgl1-/80
75

7018 p10

7018 p11

7018 p12

8322 p11

8322 p12

Lgl1+/+

98.9

92.5

96.1

96.9

94.2

Lgl1-/-

98.5

97.8

97.2

97.7

95.7
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Appendix E. Counts and proliferation of neurospheres prior to harvesting for adherent
culture assays. Proliferation of spheres prior to harvesting for adherent culture. All
replicates were propagated for 5 days except 8322 p12 for 6 days due to slow and
abnormal growth. Cells seeded and harvest are in millions of cells. Growth is referred to
-/-

as harvested over seeded values. Fold change defined as Lgl1 /Lgl1

+/+

of growth values.
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Appendix F. Western blots for all replicates of phosphorylated c-Jun and c-Jun. Western
blots on nuclear extracts from adherent cultures normalized to GAPDH on c-Jun and
phosphorylated c-Jun (Ser63). Labels are defined as follows: no treatment (NT), DMSO
at 1:2000 (DMSO), 10 µM SB203580 (SB10), 1.0 µM PD0325901 (PD1.0).
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Appendix G. Western blots for all replicates of c-Myc. Western blots on nuclear extracts
from adherent cultures normalized to GAPDH on c-Myc. Labels are defined as follows:
no treatment (NT), DMSO at 1:2000 (DMSO), 10 µM SB203580 (SB10), 1.0 µM
PD0325901 (PD1.0).
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Appendix H. Western blots for all replicates of phosphorylated p38 and p38. Western
blots on cytoplasmic extracts from adherent cultures normalized to GAPDH on p38 and
phosphorylated p38 (Thr180/Tyr182). Labels are defined as follows: no treatment (NT),
DMSO at 1:2000 (DMSO), 10 µM SB203580 (SB10), 1.0 µM PD0325901 (PD1.0).
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Appendix I. Western blots for all replicates of phosphorylated ERK and ERK. Western
blots on cytoplasmic extracts from adherent cultures normalized to GAPDH on ERK1/2
p44/42 and phosphorylated ERK1/2 (Thr202/Tyr204). Labels are defined as follows: no
treatment (NT), DMSO at 1:2000 (DMSO), 10 µM SB203580 (SB10), 1.0 µM
PD0325901 (PD1.0).
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Appendix J. Western blots for all replicates of phosphorylated JNK and JNK. Western
blots on cytoplasmic extracts from adherent cultures normalized to GAPDH on JNK1/2/3
p54/46 and phosphorylated JNK1/2/3 (Thr183/Thr183/Thr221). Labels are defined as
follows: no treatment (NT), DMSO at 1:2000 (DMSO), 10 µM SB203580 (SB10), 1.0
µM PD0325901 (PD1.0).

